Hot Features
Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Xilio Therapeutics Inc is a biotechnology company focused on harnessing the immune system to achieve deep and durable clinical responses to improve the lives of patients with cancer. Leveraging the GPS platform, they are building a pipeline of tumor-selective cytokine and checkpoint inhibitor immuno... Xilio Therapeutics Inc is a biotechnology company focused on harnessing the immune system to achieve deep and durable clinical responses to improve the lives of patients with cancer. Leveraging the GPS platform, they are building a pipeline of tumor-selective cytokine and checkpoint inhibitor immunotherapies to treat cancer. The goal is to overcome the limitations of current I-O therapies by developing products with an improved therapeutic index. Mehr anzeigen
Oncology's Best Minds Set to Meet at Upcoming 2025 ASCO Gastrointestinal Cancers Symposium PR Newswire VANCOUVER, BC, Jan. 22, 2025 USA News Group News Commentary Issued on behalf of Oncolytics...
27% preliminary response rate observed in heavily pre-treated microsatellite stable colorectal cancer (MSS CRC) patients without liver metastases Responses were accompanied by decreases in levels...
WALTHAM, Mass., Jan. 17, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology...
WALTHAM, Mass., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology...
Announces preliminary Phase 1 data for XTX301, a tumor-activated IL-12, demonstrating an improved tolerability profile over historical data for rhIL-12, with no dose-limiting toxicities Completed...
WALTHAM, Mass., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology...
WALTHAM, Mass., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.1277 | -15.3356550979 | 0.8327 | 0.85466 | 0.67 | 196989 | 0.73379766 | CS |
| 4 | -0.345 | -32.8571428571 | 1.05 | 1.2799 | 0.67 | 475605 | 1.00478122 | CS |
| 12 | -0.285 | -28.7878787879 | 0.99 | 1.28 | 0.67 | 513983 | 1.06071322 | CS |
| 26 | -0.225 | -24.1935483871 | 0.93 | 1.54 | 0.67 | 357234 | 1.0482913 | CS |
| 52 | 0.0749 | 11.8870020632 | 0.6301 | 1.93 | 0.5001 | 549660 | 1.13870322 | CS |
| 156 | -12.715 | -94.7466467958 | 13.42 | 14.86 | 0.49 | 226334 | 1.41565471 | CS |
| 260 | -14.295 | -95.3 | 15 | 27.95 | 0.49 | 219250 | 2.15232201 | CS |
| Symbol | Preis | Vol. |
|---|---|---|
| TCTMTCTM Kids IT Education Inc | US$ 0,764 (321,87%) | 729,71M |
| NVDANVIDIA Corporation | US$ 120,07 (-3,67%) | 388,53M |
| RIMEAlgorhythm Holdings Inc | US$ 0,02565 (5,12%) | 338,7M |
| BHATBlue Hat Interactive Entertainment Technology | US$ 0,0355 (-11,25%) | 236,05M |
| CLEUChina Liberal Education Holdings Ltd | US$ 0,1938 (30,77%) | 234,74M |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
